Clinical Trial Details


Back to Clinical Trials Database

Intermediate and high risk localized,completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor : a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery.

Study documentation Publications

Trial Status All trial activities ended
Dates Date of activation: 08-Dec-2004
Date Step1 close: 20-Oct-2008
Data management at EORTC Yes
Design Phase 3
Randomized open label
Targeted Sample size EORTC Groups: 350 - All Groups: 900
Study Staff
Type of cancer
Participating groups
Protocol summary
NCT number NCT00103168
EudraCT 2004-001810-16